Royalty Pharma Officer Files Form 144 to Sell $238K in Shares Under 10b5-1 Plan

Executive Summary

Royalty Pharma plc officer Marshall Urist filed a Form 144 on September 28, 2026, declaring the intent to sell 4,126 Class A Ordinary Shares through Merrill Lynch. The aggregate market value of the proposed transaction is $238,812.88, equating to approximately $57.88 per share.

Transaction Details

• Securities to be Sold: 4,126 Class A Ordinary Shares (Common Stock)
• Acquisition Source: Acquired on August 5, 2026, as an Equity Performance Award under the issuer's equity compensation program.
• Trading Plan: The planned sale is being conducted pursuant to a pre-established Rule 10b5-1 trading plan adopted on June 26, 2026.
• Past Sales (Past 3 Months): The filing discloses multiple prior sales, including 13,684 shares on May 14, 2026 ($726,137.82), 13,684 shares on May 20, 2026 ($721,837.21), 9,098 shares on June 24, 2026 ($502,066.55), and 9,099 shares on July 1, 2026 ($508,453.82).

Market Impact & Significance

The proposed disposition represents a routine liquidity event under a 10b5-1 plan following the vesting/settlement of performance equity awards. Relative to Royalty Pharma plc's outstanding float of over 445 million shares, the 4,126 shares represent a negligible fraction (<0.001%) and carry low trading significance.